MedStar Authors catalog › Details for: Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Normal view MARC view ISBD view

Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

by Ratner, Robert E.
Citation: Diabetes Care. 37(6):1706-11, 2014 Jun..Journal: Diabetes care.ISSN: 0149-5992.Full author list: Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA.UI/PMID: 24705615.Subject(s): *Adiponectin/bl [Blood] | Blood Glucose/an [Analysis] | Cohort Studies | *Diabetes Mellitus, Type 2/bl [Blood] | *Diabetes Mellitus, Type 2/dt [Drug Therapy] | Disease Progression | Female | Follow-Up Studies | Glucose Intolerance/bl [Blood] | *Glucose Intolerance/dt [Drug Therapy] | Glucose Tolerance Test | Humans | *Hypoglycemic Agents/tu [Therapeutic Use] | Insulin/tu [Therapeutic Use] | *Insulin Resistance | Insulin-Secreting Cells/me [Metabolism] | Male | Middle Aged | *Thiazolidinediones/tu [Therapeutic Use]Institution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal Article | Randomized Controlled Trial | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov't | Research Support, U.S. Gov't, Non-P.H.SOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: Diabetes Care. 37(6):1706-11, 2014 Jun.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006.Abstract: OBJECTIVE: Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status.Abstract: RESEARCH DESIGN AND METHODS: A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.Abstract: RESULTS: Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved beta-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 +/- 0.5 to 38 +/- 2.5 mug/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group.Abstract: CONCLUSIONS: Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.Copyright � 2014 by the American Diabetes Association.

Powered by Koha